CGON (CG Oncology) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGON CG Oncology Inc CGON
12 GF Score
Price $71.41
! 5 Warning Signs
View Full Analysis

What is CG Oncology Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

CGON
12GF Score
CG Oncology Inc CGON
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.41
Price